MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

NEW YORK, April 16, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled,...

from PR Newswire: https://ift.tt/2KbPlQn